ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0902

A Novel Approach to study ANA+ B Cells in Lupus Integrating Flow Cytometry with Single-Cell culture

Deisy Muriel Velez arteaga1, Yemil Atisha Fregoso2, Hasret Gunduz3 and Betty Diamond4, 1The Elmezzi School of Molecular Medicine, New Rochelle, NY, 2The Feinstein Institute, Long Island, NY, 3The Feinstein Institute, Long Island, 4The Feinstein Institutes for Medical Research, Manhasset, NY

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, immunology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Studying antinuclear antibody (ANA) producing B cells at the single-cell level offers critical insights into their fine specificity and functional characteristics. However, conventional techniques including bulk B cell cultures, ELISpot assays, and single-cell sequencing present several limitations. To overcome some of these limitations, we developed an integrated platform that combines flow cytometric detection of ANA⁺ B cells with an optimized single-B cell culture system (Nojima).

Methods: We employed a flow cytometry assay using biotinylated nuclear extracts to detect ANA reactive B cells, followed by single cell sorting and culture in the presence of feeder cells expressing CD40L and adding BAFF, IL-2, IL-21 (Figure 1).

Results: This approach enabled the isolation and in vitro expansion of ANA-producing B cells coming from patients with SLE and healthy donors from naïve, marginal zone and memory B cell subsets. Following 26 days of culture, a high proportion of wells produced significant immunoglobulin levels: 82% of naïve, 67% of marginal zone, and 57% of IgG⁺ memory B cell cultures exceeded 1 µg/mL. ANA reactivity in culture supernatants was confirmed by HEp-2 cell staining (shown in figure 2), yielding a sensitivity of 95% and specificity of 68%, validating the functional identity of the expanded B cells. Studying previously sorted ANA+ cells significantly increases the efficiency of the assay. In order to study the immunoglobulin form 100 ANA⁺ cells would ordinarily require screening 2,857 B cells (assuming ANA prevalence of 5%), whereas our approach reduces this to just 150 cells.

Conclusion: This method provides a robust platform for isolating and expanding ANA-producing B cells, enabling the production of autoantibodies for further study. The approach has potential applications in elucidating SLE pathogenesis.

Supporting image 1Figure 1: Experimental approach. Seeding the feeder cells until they reach 70% confluence. Irradiating the tissue culture plates with the feeder cells and then sort the cells directly into the tissue plate. Add cytokines and change media replacing cytokines every 3 days. End the culture by day 26, estimate the immunoglobulin production on the supernatant by ELISA. Finally validate the method by testing the supernatants in Hep2 cells.

Supporting image 2Table 1. Percentage of wells producing immunoglobulin by day 26 in 96-well single-cell cultures of B cell subsets from ANA-negative and ANA-positive donors using two seeding methods.

Values represent the proportion of wells (out of total plated) that produced detectable IgM (for naïve and marginal zone B cells) or IgG (for memory B cells) above 1 and 10ug/mL threshold. Comparisons are shown for manually seeded versus index plate-sorted cells, grouped by ANA status.

Supporting image 3Figure 2. Hep 2 Staining in ANA sorted cells from a patient with SLE showing different nuclear patterns.


Disclosures: D. Velez arteaga: None; Y. Atisha Fregoso: None; H. Gunduz: None; B. Diamond: None.

To cite this abstract in AMA style:

Velez arteaga D, Atisha Fregoso Y, Gunduz H, Diamond B. A Novel Approach to study ANA+ B Cells in Lupus Integrating Flow Cytometry with Single-Cell culture [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/a-novel-approach-to-study-ana-b-cells-in-lupus-integrating-flow-cytometry-with-single-cell-culture/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-approach-to-study-ana-b-cells-in-lupus-integrating-flow-cytometry-with-single-cell-culture/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology